{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-264392","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2026-06-09T22:11:53+00:00","discovered_at":"2026-06-10T10:05:00.211265+00:00","generated_at":"2026-06-10T10:10:02.102930+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Director Brian Thomas resigns from Metagenomi board; shareholders re-elect Eckhardt, Bjerkholt and ratify PwC as auditor","bullets":["Brian C. Thomas, Ph.D. resigned from the board effective June 9, 2026, with no disagreement with the company.","Juergen Eckhardt and Eric Bjerkholt elected as Class II directors to serve until 2029 annual meeting.","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 18,483,295 votes for, 51,847 against.","Quorum of 19,116,207 shares present out of 37,647,057 outstanding at the June 9, 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-264392","json":"https://secwatch.observer/filing/0001193125-26-264392.json","markdown":"https://secwatch.observer/filing/0001193125-26-264392.md","text":"https://secwatch.observer/filing/0001193125-26-264392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:10:02.102930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5bb1b5e8a","claim":"Brian C. Thomas resigned as director at Metagenomi Therapeutics, Inc..","evidence_excerpt":"On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"4c5826be28a9593e515e415771aeada66590e372","claim":"Metagenomi Therapeutics, Inc. shareholders approved Election of Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II Directors at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 1 - Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. were elected as Class II Directors to serve until the Company’s 2029 annual meeting of stockholders, and until their respective successor shall have been duly elected and qualified, or until their earlier death, resignation or removal, based on the following votes: Class II Director Nominee For Withheld Broker Non-Votes Juergen Eckhardt, M.D., M.B.A. 7,296,718 1,436,882 10,382,607 Eric Bjerkholt, M.B.A. 8,251,289 482,311 10,382,607","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"7fb07ffcd53ed9b272119dafd8627af9d18d6804","claim":"Metagenomi Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 2 – The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstentions 18,483,295 51,847 581,065","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}